BioAtla, Inc. announced that the Nasdaq Listing and Hearing Review Council affirmed its decision to delist the company's common stock from The Nasdaq Capital Market due to non-compliance with minimum bid price and stockholders' equity requirements. Trading of the Common Stock is scheduled to be suspended at the opening of business on August 31, 2026, after which the shares will likely trade on the OTC Markets system under the symbol BCAB. The company noted that this delisting may have a material adverse effect on trading price and volume and expressed no assurance regarding the maintenance of an active market for its shares. BioAtla, Inc. operates in the biotechnology industry, focusing on the development of covalent antibody-based (CAB) technology platforms and product candidates.